Tyra Biosciences Appoints New Chief Medical Officer
Ticker: TYRA · Form: 8-K · Filed: 2026-04-02T16:02:06-04:00
Sentiment: neutral
Topics: executive-appointment, personnel-change, compensation
TL;DR
Tyra Bio names Todd Brady as CMO, effective April 1st. New role comes with $475k salary + bonus.
AI Summary
On April 2, 2026, Tyra Biosciences, Inc. filed an 8-K report detailing changes in its executive officers. Specifically, the filing announced the appointment of Todd A. Brady as Chief Medical Officer, effective April 1, 2026. Brady's compensation package includes a base salary of $475,000 and a target annual bonus of 40% of his base salary.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction and clinical development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions can signal shifts in company strategy or potential challenges, warranting closer observation.
Key Numbers
- $475,000 — CMO Base Salary (Annual base compensation for the new Chief Medical Officer, Todd A. Brady.)
- 40% — CMO Target Bonus (Annual bonus potential for the new Chief Medical Officer, based on his base salary.)
Key Players & Entities
- Tyra Biosciences, Inc. (company) — Company filing the report
- Todd A. Brady (person) — Newly appointed Chief Medical Officer
- $475,000 (dollar_amount) — Todd A. Brady's base salary
- 40% (dollar_amount) — Todd A. Brady's target annual bonus percentage
- April 1, 2026 (date) — Effective date of Todd A. Brady's appointment
- April 2, 2026 (date) — Filing date of the 8-K report
FAQ
Who is the new Chief Medical Officer at Tyra Biosciences?
Todd A. Brady was appointed as the new Chief Medical Officer.
When did Todd A. Brady's appointment become effective?
The appointment of Todd A. Brady became effective on April 1, 2026.
What is Todd A. Brady's base salary?
Todd A. Brady's base salary is $475,000.
What is the target annual bonus for Todd A. Brady?
Todd A. Brady has a target annual bonus of 40% of his base salary.
What type of filing is this for Tyra Biosciences?
This is a Form 8-K, a Current Report filed by Tyra Biosciences, Inc.
From the Filing
EDGAR Filing Documents for 0001193125-26-140027 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-140027 Filing Date 2026-04-02 Accepted 2026-04-02 16:02:06 Documents 11 Period of Report 2026-04-01 Items Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d136343d8k.htm iXBRL 8-K 23544 Complete submission text file 0001193125-26-140027.txt 137020 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA tyra-20260401.xsd EX-101.SCH 2826 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tyra-20260401_lab.xml EX-101.LAB 17975 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tyra-20260401_pre.xml EX-101.PRE 11241 14 EXTRACTED XBRL INSTANCE DOCUMENT d136343d8k_htm.xml XML 3629 Mailing Address 2656 STATE STREET CARLSBAD CA 92008 Business Address 2656 STATE STREET CARLSBAD CA 92008 (619) 728-4760 Tyra Biosciences, Inc. (Filer) CIK : 0001863127 (see all company filings) EIN. : 831476348 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40800 | Film No.: 26833181 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)